With the coveted trillion-dollar valuation, a new pinnacle of success is approaching for a limited number of companies. This once-impossible milestone is now within reach for three formidable potentia

Where Will Eli Lilly Be in 5 Years?

01:45am, Sunday, 18'th Feb 2024
Its core therapeutic area will be a major tailwind in the next five years. The drugmaker should make significant progress in other fields, too.
As the craze surrounding weight loss drugs like GLP-1s continues, many investors are wondering how to capitalize on the massive valuation given to this sector by many on Wall Street. Matt Higgins, RSE
The “Halftime Report” Investment Committee debate the biggest analyst calls of the day.
Morgan Stanley analyst Terence Flynn increases his price target on shares of the drugmaker to $950 from $805.
A year ago, we wouldn't discuss replacing Tesla (NASDAQ: TSLA ) as one of the Magnificent 7 stocks. However, losing 50% of its value since November, the drum beat gets louder to replace Elon Musk's ba
The SPDR S&P 500 ETF Trust NYSEARCA: SPY is trading at new highs, but as the sharp pullback on February 13 showed, the rally may be showing signs of cracking.
Tiger Global has slashed its positions in four of the five Magnificent Seven tech stocks that account for almost half of its portfolio, while upping its stake in Amazon.com and piling into semiconduct
It is entirely fair to state that weight loss treatments have massive transformational power. US FDA approval of weight loss medicines could help shrink millions of waistlines.
Amgen is the latest big pharma to join the gold rush to treat obesity. Its candidate is distinct from the medicines by Eli Lilly and Novo Nordisk.
'Mad Money' host Jim Cramer looks at the top performing stocks on the S&P 500 as it reached the 5,000 milestone.
Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to to discuss the latest raise to Eli Lilly.
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
BioAge Labs, a biotech startup collaborating with Eli Lilly for trialing its obesity therapy, said on Tuesday it had raised $170 million in its latest funding round.
Eli Lilly and Novo Nordisk stocks have soared, thanks largely to their weight-loss drugs. However, analysts think that another big pharma stock will perform much better over the near term.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE